What's Happening?
Kelun-Biotech has presented positive Phase 3 data for trastuzumab botidotin, a HER2-directed antibody-drug conjugate (ADC), at the 2025 European Society for Medical Oncology Congress. The study compared
trastuzumab botidotin to trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable or metastatic breast cancer. The results showed a significant improvement in progression-free survival and overall response rate with trastuzumab botidotin. The treatment was well-tolerated, with manageable adverse events.
Why It's Important?
The findings from this study provide a new treatment option for patients with HER2-positive breast cancer, particularly those who have received prior anti-HER2 therapies. Trastuzumab botidotin's superior efficacy over T-DM1 could lead to changes in clinical practice guidelines and offer patients a more effective therapy with a manageable safety profile. This advancement underscores the potential of ADCs in improving cancer treatment outcomes.
What's Next?
Kelun-Biotech plans to continue the development of trastuzumab botidotin, potentially expanding its use to other HER2-positive cancers. The company is also conducting additional studies to further evaluate the drug's efficacy and safety. These efforts aim to solidify trastuzumab botidotin's role in the treatment landscape and provide more personalized treatment options for patients with HER2-positive cancers.
